Humanigen CEO to Present at Inaugural LD Micro Virtual Conference
March 1, 2018
BRISBANE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- Humanigen, Inc. (OTCQB:HGEN), a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments, today announced that Cameron Durrant, M.D., chairman and CEO, will present a company overview at the LD Micro Virtual Conference on Tuesday, March 6, 2018, at 11 a.m. EST (8 a.m. PST).
Dr. Durrant will address Humanigen’s ongoing transformation as a biotechnology company focused on potentially making chimeric antigen receptor (CAR-T) therapy safer, better and more routine.
The presentation will be available at http://www.investorcalendar.com/console/conference/?id=26410 and will also include answering questions from investors. The LD Micro Virtual Conference will be held via webcast and will feature over 60 small- and micro-cap companies.
A replay of the presentation will be available afterward on the Humanigen website at https://www.humanigen.com/events.
Humanigen, Inc. is a biopharmaceutical company pursuing cutting-edge science to develop its proprietary monoclonal antibodies for immunotherapy and oncology treatments. Derived from the company’s Humaneered® platform, lenzilumab and ifabotuzumab are lead compounds in the portfolio of monoclonal antibodies with first-in-class mechanisms. Lenzilumab, which targets granulocyte-macrophage colony-stimulating factor (GM-CSF), is in development as a potential medicine to make chimeric antigen receptor T-cell (CAR-T) therapy safer and more effective, as well as a potential treatment for rare hematologic cancers such as chronic myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). Ifabotuzumab, which targets Ephrin type-A receptor 3 (EphA3), is being explored as a potential treatment for glioblastoma multiforme (GBM) and other deadly cancers, as well as a platform for creation of CAR-T and bispecific antibodies. For more information, visit www.humanigen.com.
Source: Humanigen, Inc.
Released March 1, 2018